MHRA’s National assessment procedure for medicines guidance was updated on 24 February 2026. The page explains the agency’s national assessment procedure for marketing authorisation applications in the UK.
Even though this is not a pharmacovigilance-specific page, it matters to PV teams because authorization pathways shape the regulatory environment in which safety obligations sit. When market access pathways evolve, downstream implications can appear in lifecycle management, post-authorisation planning, and internal governance. That last point is an inference, but it is a practical one.
For PV Watch Daily readers, this is part of the bigger UK picture: regulatory structure and pharmacovigilance operations are not separate worlds. They intersect more often than organizations sometimes assume.
0 Comments